Statement
-
Statement
Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
05.25.2022
Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers
-
Statement
Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
04.14.2022
See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.
-
Statement
Incubate Letter in Opposition to MA S. 2774
04.07.2022
See Incubate's letter to the Massachusetts state legislature in opposition to S. 2774
-
Statement
Incubate Letter in Opposition to CT SB-13
03.29.2022
See Incubate's letter to Connecticut legislature opposing SB-13.
-
Statement
Gaurav Gupta Comment on the Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
02.10.2022
Incubate Advisory Council member Gaurav Gupta's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
Statement
Incubate Comment on the Proposed Decision Memo for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
02.10.2022
Executive Director John Stanford's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
Statement
Moonshot Statement
02.02.2022
Read Incubate Executive Director John Stanford's statement on President BIden's Moonshot initiative.
-
Statement
Leading Venture Capital Group Alarmed By Build Back Better Act’s Prescription Drug Provision
11.19.2021
John Stanford, Executive Director of Incubate, a coalition of America's early-stage life sciences investors, issued the following statement on congressional Democrats' passage of the Build Back Better Act
-
Statement
Leading Venture Capital Group Concerned with Prescription Drug Deal
11.04.2021
"As investors in biotechnology and pharmaceuticals, we're highly concerned about the potential consequences of the new drug-pricing legislation before Congress in the Build Back Better Act."
-
Statement
-
Statement
Letter to President Biden, Secretary Becerra, Speaker Pelosi, Minority Leader McCarthy, Senate Majority Leader Schumer, and Senate Minority Leader McConnell opposing HR 3
09.08.2021
Members of the VC community voice concerns over HR 3 to policymakers
-
Statement
Incubate Statement on Introduction of the PASTEUR Act
06.22.2021
Incubate commends Senators Michael Bennet (D-CO) and Todd Young (R-IN) and Representatives Mike Doyle (D-PA) and Drew Ferguson (R-GA) for re-introducing the Pioneering Antimicrobial Subscriptions to End Up surging Resistance (PASTEUR) Act.